2023
Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
Dimond M, Ibrahim N, Fiuzat M, McMurray J, Lindenfeld J, Ahmad T, Bozkurt B, Bristow M, Butler J, Carson P, Felker G, Jessup M, Murillo J, Kondo T, Solomon S, Abraham W, O'Connor C, Psotka M. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping. JACC Heart Failure 2023, 12: 451-460. PMID: 38099892, DOI: 10.1016/j.jchf.2023.11.005.Peer-Reviewed Original ResearchElectronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure
Fuery M, Kadhim B, Samsky M, Freeman J, Clark K, Desai N, Wilson F, Ahmed T, Ahmad T. Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure. Current Heart Failure Reports 2023, 20: 280-286. PMID: 37552356, DOI: 10.1007/s11897-023-00614-0.Peer-Reviewed Original ResearchConceptsHeart failure patientsFailure patientsElectronic health recordsEHR alertClinical trialsRandomized clinical trialsCare of patientsQuality of careHeart failureClinician satisfactionRandomized fashionRecent FindingsTherePatientsUnmet needPatient careClinical decisionEvidence-based decisionsFuture interventionsCareHealth recordsTrialsCliniciansInterventionFindingsThereUse of patient‐reported outcomes in heart failure: from clinical trials to routine practice
Savarese G, Lindenfeld J, Stolfo D, Adams K, Ahmad T, Desai N, Ammirati E, Gottlieb S, Psotka M, Rosano G, Allen L. Use of patient‐reported outcomes in heart failure: from clinical trials to routine practice. European Journal Of Heart Failure 2023, 25: 139-151. PMID: 36644876, DOI: 10.1002/ejhf.2778.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesHeart failureHF careApplication of PROsClinical practiceDisease statusMortality/morbidityPatient-centered approachQuality of lifeDaily clinical routinePerception of diseasePhysician assessmentClinical trialsTraditional careComplex syndromeOwn carePatient experiencePatient's lifeRoutine practiceSymptom severityClinical routineModalities of usePatient's standpointCareTrials
2022
Functional and Symptomatic Clinical Trial Endpoints The HFC-ARC Scientific Expert Panel
Psotka M, Abraham W, Fiuzat M, Filippatos G, Lindenfeld J, Ahmad T, Felker G, Jacob R, Kitzman D, Leifer E, Lewis E, Mentz R, Nkulikiyinka R, Ni W, Schaber D, Sharma A, Solomon S, Stockbridge N, Teerlink J, Unger E, Whellan D, Wittes J, Anker S, O'Connor C. Functional and Symptomatic Clinical Trial Endpoints The HFC-ARC Scientific Expert Panel. JACC Heart Failure 2022, 10: 889-901. PMID: 36456063, DOI: 10.1016/j.jchf.2022.09.012.Peer-Reviewed Original ResearchConceptsAcademic Research ConsortiumHeart failureSubmaximal exercise tolerancePatient-reported outcomesCardiovascular clinical researchResearch ConsortiumExercise toleranceScientific Expert PanelPatients' qualityFunctional statusClinical trialsLife endpointsConsensus recommendationsClinical utilityDrug AdministrationCardiovascular therapeuticsClinical researchU.S. FoodExpert panelPotential endpointsNational InstituteEvidence generationTrialsEndpointAcademic investigators
2021
REVeAL-HF Design and Rationale of a Pragmatic Randomized Controlled Trial Embedded Within Routine Clinical Practice
Ahmad T, Yamamoto Y, Biswas A, Ghazi L, Martin M, Simonov M, Hsiao A, Kashyap N, Velazquez EJ, Desai NR, Wilson FP. REVeAL-HF Design and Rationale of a Pragmatic Randomized Controlled Trial Embedded Within Routine Clinical Practice. JACC Heart Failure 2021, 9: 409-419. PMID: 33992566, DOI: 10.1016/j.jchf.2021.03.006.Peer-Reviewed Original ResearchConceptsHeart failurePatient outcomesClinical decision makingN-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsPragmatic Randomized Controlled TrialIntravenous diuretic agentsNatriuretic peptide levelsRandomized Controlled TrialsRoutine clinical practiceEvidence-based interventionsElectronic health recordsControlled TrialsPatient populationAccurate prognosticationCommon causeDiuretic agentsPeptide levelsClinical practicePg/TrialsHealth recordsSignificant riskMortalityOutcomes
2020
Conduct of Clinical Trials in the Era of COVID-19 JACC Scientific Expert Panel
Psotka MA, Abraham WT, Fiuzat M, Filippatos G, Lindenfeld J, Ahmad T, Bhatt AS, Carson PE, Cleland JGF, Felker GM, Januzzi JL, Kitzman DW, Leifer ES, Lewis EF, McMurray JJV, Mentz RJ, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Vardeny O, Whellan DJ, Wittes J, Anker SD, O'Connor CM. Conduct of Clinical Trials in the Era of COVID-19 JACC Scientific Expert Panel. Journal Of The American College Of Cardiology 2020, 76: 2368-2378. PMID: 33183511, PMCID: PMC7836888, DOI: 10.1016/j.jacc.2020.09.544.Peer-Reviewed Original ResearchConceptsAcademic Research ConsortiumClinical trialsExpert consensus recommendationsResearch ConsortiumScientific Expert PanelHeart failureCardiovascular diseaseConsensus recommendationsClinical careDrug AdministrationCoronavirus diseaseU.S. FoodExpert panelNational InstituteTrialsCOVID-19 pandemicDiseaseAcademic investigatorsHeartKey recommendationsSeries of meetingsPandemicPatientsAdministrationCarePATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
Sharma A, Ofstad A, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George J, Hantel S, Desai N, Mentz R. PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2020, 36: s71. DOI: 10.1016/j.cjca.2020.07.143.Peer-Reviewed Original Research
2013
Therapeutic Implications of Biomarkers in Chronic Heart Failure
Ahmad T, O'Connor C. Therapeutic Implications of Biomarkers in Chronic Heart Failure. Clinical Pharmacology & Therapeutics 2013, 94: 468-479. PMID: 23856627, DOI: 10.1038/clpt.2013.139.Peer-Reviewed Original ResearchConceptsChronic heart failureHeart failureTherapeutic implicationsBiomarker-guided clinical trialsTreatment of HFPotential therapeutic implicationsClinical trial designImportant therapeutic implicationsUse of biomarkersHemodynamic disordersClinical trialsClinical careTrial designTherapeutic potentialBiomarker studiesMolecular biomarkersBiomarkersMolecular dysfunctionMolecular pathwaysDysfunctionFailurePathophysiologySyndromeTrialsCare
2012
INTERACTION BETWEEN ST2 LEVELS AND EXERCISE TRAINING IN PATIENTS WITH CHRONIC HEART FAILURE: ANALYSIS FROM THE HF-ACTION TRIAL
Ahmad T, Felker G, Fiuzat M, Thompson V, Shaw L, Adams K, Whellan D, Donahue M, Kitzman D, Pina I, Zannad F, Kraus W, O'Connor C. INTERACTION BETWEEN ST2 LEVELS AND EXERCISE TRAINING IN PATIENTS WITH CHRONIC HEART FAILURE: ANALYSIS FROM THE HF-ACTION TRIAL. Journal Of The American College Of Cardiology 2012, 59: e940. DOI: 10.1016/s0735-1097(12)60941-3.Peer-Reviewed Original Research